持続性高コレステロール血症患者におけるエビナクマブ（REGN1500）の研究

基本情報

NCT ID

NCT03175367

ステータス

完了

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

272

治験依頼者名

Regeneron Pharmaceuticals

概要

The primary objective of the study is to evaluate the reduction of LDL-C by evinacumab in comparison to placebo after 16 weeks in patients with primary hypercholesterolemia (HeFH, or non-HeFH with a history of clinical ASCVD) with persistent hypercholesterolemia despite receiving maximally-tolerated LMT. Persistent hypercholesterolemia is defined as LDL-C ≥70 mg/dL (1.81 mmol/L) for those patients with clinical ASCVD and LDL-C ≥100 mg/dL (2.59 mmol/L) for those patients without clinical ASCVD.

対象疾患

介入

依頼者（Sponsor）

実施施設 (4)